[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202193211A1 - Лечение синуклеопатий - Google Patents

Лечение синуклеопатий

Info

Publication number
EA202193211A1
EA202193211A1 EA202193211A EA202193211A EA202193211A1 EA 202193211 A1 EA202193211 A1 EA 202193211A1 EA 202193211 A EA202193211 A EA 202193211A EA 202193211 A EA202193211 A EA 202193211A EA 202193211 A1 EA202193211 A1 EA 202193211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synucleopathies
treatment
synucleopathy
administering
treating
Prior art date
Application number
EA202193211A
Other languages
English (en)
Inventor
Нитин Кришнаджи Дамле
Эндрю Майкл Голдфайн
Санджайкумар Нандлал Мандхане
Original Assignee
Сан Фарма Эдванст Рисерч Компани Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Эдванст Рисерч Компани Лтд. filed Critical Сан Фарма Эдванст Рисерч Компани Лтд.
Publication of EA202193211A1 publication Critical patent/EA202193211A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Способ лечения или предупреждения синуклеопатий у субъекта-человека, включающий введение терапевтически эффективного количества соединения формулы 1или его фармацевтически приемлемой соли.
EA202193211A 2019-06-11 2020-06-09 Лечение синуклеопатий EA202193211A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921023164 2019-06-11
PCT/IB2020/055425 WO2020250133A1 (en) 2019-06-11 2020-06-09 Treatment for synucleinopathies

Publications (1)

Publication Number Publication Date
EA202193211A1 true EA202193211A1 (ru) 2022-03-30

Family

ID=71094647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193211A EA202193211A1 (ru) 2019-06-11 2020-06-09 Лечение синуклеопатий

Country Status (14)

Country Link
US (1) US20220257582A1 (ru)
EP (1) EP3982964A1 (ru)
JP (1) JP2022536331A (ru)
KR (1) KR20220024463A (ru)
CN (1) CN114040763A (ru)
AU (1) AU2020292703A1 (ru)
BR (1) BR112021024835A2 (ru)
CA (1) CA3142899A1 (ru)
CL (1) CL2021003303A1 (ru)
EA (1) EA202193211A1 (ru)
IL (1) IL288797A (ru)
MA (1) MA56179A (ru)
MX (1) MX2021015390A (ru)
WO (1) WO2020250133A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4508645B2 (ja) 2002-01-04 2010-07-21 ザ ロックフェラー ユニバーシティー アミロイド−βペプチド関連疾患の予防および治療用の組成物および方法
EP1487451A4 (en) 2002-03-21 2007-10-03 Dana Farber Cancer Inst Inc INHIBITION OF CELLULAR DEATH RESPONSES INDUCED BY OXIDATIVE STRESS
TWI343806B (en) 2003-07-01 2011-06-21 Nat Health Research Institutes Methods of inhibiting neurodegenerative disease
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
AU2012208388C1 (en) 2011-01-21 2017-04-27 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
JP2014510154A (ja) 2011-04-07 2014-04-24 アリアド・ファーマシューティカルズ・インコーポレイテッド 神経変性疾患の治療方法及び治療用組成物
US9474753B2 (en) * 2012-05-02 2016-10-25 Georgetown University Treating neural disease with tyrosine kinase inhibitors
WO2017208267A1 (en) 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
CA3142899A1 (en) 2020-12-17
JP2022536331A (ja) 2022-08-15
KR20220024463A (ko) 2022-03-03
BR112021024835A2 (pt) 2022-01-18
MX2021015390A (es) 2022-01-24
WO2020250133A1 (en) 2020-12-17
CN114040763A (zh) 2022-02-11
EP3982964A1 (en) 2022-04-20
IL288797A (en) 2022-02-01
AU2020292703A1 (en) 2022-01-27
CL2021003303A1 (es) 2022-08-19
US20220257582A1 (en) 2022-08-18
MA56179A (fr) 2022-04-20

Similar Documents

Publication Publication Date Title
EP4331677A3 (en) Methods of treating feline coronavirus infections
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2022000143A (es) Metodos novedosos.
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
EA202193007A1 (ru) Соединения пирролидина
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2022003845A (es) Tratamientos cognitivos medicinales.
ZA202212095B (en) Il4i1 inhibitors and methods of use
WO2020128614A8 (en) Method for treating interstital lung disease
EA202193211A1 (ru) Лечение синуклеопатий
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий
MX2019004200A (es) Terapia de combinacion.
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.